- Home
- CAC vs ESPR Comparison
CAC vs ESPR Comparison
Compare CAC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- ESPR
- Stock Information
- Founded
- CAC 1875
- ESPR 2008
- Country
- CAC United States
- ESPR United States
- Employees
- CAC N/A
- ESPR N/A
- Industry
- CAC Major Banks
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- ESPR Health Care
- Exchange
- CAC Nasdaq
- ESPR Nasdaq
- Market Cap
- CAC 680.5M
- ESPR 660.1M
- IPO Year
- CAC 1997
- ESPR 2013
- Fundamental
- Price
- CAC $38.83
- ESPR $2.66
- Analyst Decision
- CAC Buy
- ESPR Buy
- Analyst Count
- CAC 3
- ESPR 6
- Target Price
- CAC $47.33
- ESPR $6.50
- AVG Volume (30 Days)
- CAC 76.5K
- ESPR 5.7M
- Earning Date
- CAC 10-28-2025
- ESPR 11-06-2025
- Dividend Yield
- CAC 4.33%
- ESPR N/A
- EPS Growth
- CAC 9.13
- ESPR N/A
- EPS
- CAC 3.49
- ESPR N/A
- Revenue
- CAC $215,172,000.00
- ESPR $303,802,000.00
- Revenue This Year
- CAC $44.50
- ESPR $18.83
- Revenue Next Year
- CAC $7.03
- ESPR N/A
- P/E Ratio
- CAC $11.12
- ESPR N/A
- Revenue Growth
- CAC 27.50
- ESPR 2.83
- 52 Week Low
- CAC $34.53
- ESPR $0.69
- 52 Week High
- CAC $50.07
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CAC 52.74
- ESPR 47.45
- Support Level
- CAC $37.78
- ESPR $2.42
- Resistance Level
- CAC $39.35
- ESPR $2.99
- Average True Range (ATR)
- CAC 0.92
- ESPR 0.18
- MACD
- CAC 0.22
- ESPR -0.04
- Stochastic Oscillator
- CAC 59.62
- ESPR 32.27
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.